2023 ASCO Annual Meeting: Phase 1 Study of Pritumumab in Brain Cancer
CLICK TO DOWNLOAD PDF
Pritumumab is a proprietary monoclonal antibody (mAb) targeting a novel antigen on cancer cells.
Pritumumab has received FDA orphan drug status
NASCENT BIOTECH NEWS
